

IMAGE



Infographic: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months: the VICI study

Imran H. Yusuf^{1,2,✉}, Christin Henein^{3,4} and Sobha Sivaprasad^{1,4}

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023

Eye (2024) 38:33–34; https://doi.org/10.1038/s41433-023-02394-2

Patients with treatment naïve chronic serous chorioretinopathy for 4 months or more were included. Mean BCVA at baseline was 77 letters versus 78 letters, baseline CRT was 360 µm versus 322 µm and SRF thickness was 147 µm versus 119 µm in the eplerenone and placebo groups, respectively. There were no benefits of eplerenone observed in any endpoint. Six patients in the placebo group and three in the eplerenone group received photodynamic therapy as usual care.

CSCR – chronic central serous chorioretinopathy; CNV – choroidal neovascularisation; BCVA – best corrected visual acuity; mg – milligram; CI – confidence interval; CRT – central retinal thickness on optical coherence tomography imaging; SRF – subretinal fluid; µm – micrometres.


Reference: Lotery et al. “Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial”. The Lancet, 2020;395:294–303.

FUNDING

Medical Research Council UK (MR/R000735/1).

COMPETING INTERESTS

The authors declare no competing interests.



¹Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. ²Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford OX3 9DU, UK. ³UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. ⁴NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. ✉email: Imran.yusuf@eye.ox.ac.uk

Received: 30 November 2022 Revised: 10 December 2022 Accepted: 13 January 2023
 Published online: 21 April 2023

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Imran H. Yusuf.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Please note that the infographic is best viewed online.